Navigation Links
Biotech Strategy 2012 - Licensing, Collaboration, and M&A Trends

NEW YORK, Jan. 31, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Biotech Strategy 2012 - Licensing, Collaboration, and M&A Trends

Biotech Strategy 2012 - Licensing, Collaboration, and M&A Trends

Summary GlobalData's Biotech Strategy 2012 - Licensing, Collaboration, and M&A Trends report analyzes 20 strategic deals struck by leading and promising biotech companies. The terms and strategic drivers of these deals are analyzed based on acquisition costs, strategic fit, potential revenues, competitive advantage as well as other measures to illustrate the strategies different companies are currently using to gain market share, increase shareholder value and bring innovative and life-saving products to the booming global pharmaceuticals market. This report is an essential source of information and analysis on global strategic deals involving the top players in the global pharmaceuticals market.Scope - The report provides full details of 20 significant deals from Q3 2011 to Q3 2012 involving promising biotech companies including deal terms and payment structure. The report provides analysis of the key drivers, trends, and strategies behind deals undertaken by biotech companies across important geographic regions including the US, EU, Asia-Pacific, Brazil, Russia, India, China, and other emerging markets. The report covers the six major therapy areas of cardiovascular disease, central nervous system (CNS), diabetes and metabolic, immunology, oncology, and respiratory. The report contains expert insights on the corporate strategies of emerging biotech companies seeking competitive advantage in the pharmaceuticals marketplace.Reasons to buy - Analyze and emulate the strategies that promising biotech companies are using to gain market share in the increasingly competitive global pharmaceuticals market.

- Understand the various factors considered when structuring deal terms in strategic acquisitions, mergers, collaborations, and licensing.

- Identify potential takeover targets and partners, thereby maximizing your opportunities for consolidation, investment, and strategic partnerships.

- Organize your sales and marketing efforts by identifying the business regions and segments to maximize opportunities for consolidation, investment and strategic partnerships.

Table of Contents

1 Table of CContents 51.1 List of Tables 81.2 List of Figures 82 Introduction 92.1 Catalyst 92.1.1 Key Questions Answered 92.1.2 Key Benefits 102.2 Upcoming Related Reports 102.3 Recently published reports: 103 Historical Dealmaking Trends 113.1 Overview 113.2 Leading Deal Drivers 113.2.1 The Patent Cliff 113.2.2 Lack of R&D Innovation 143.2.3 Strategic Shift to Emerging Markets 153.3 Overall Deals in Review 153.3.1 Review by Deal Type 153.3.2 Review by Therapy Area 183.4 Biotech Deals in Review 194 Mergers and Acquisitions 204.1 Overview 204.2 Gilead Completes $11.1 Billion Acquisition of Pharmasset 224.2.1 Deal Description 224.2.2 Deal Analysis 234.3 GSK Acquires HGS in $3.6 Billion Deal 244.3.1 Deal Description 244.3.2 Deal Analysis 244.4 Valeant Pharmaceuticals Agrees $2.6 Billion Cash Deal for Medicis Acquisition 274.4.1 Deal Description 274.4.2 Deal Analysis 274.5 Amgen Acquires Micromet in $1.1 Billion Deal 294.5.1 Deal Description 294.5.2 Deal Analysis 294.6 Alexion Completes Acquisition of Enobia Pharma in $1.1 Billion Deal 314.6.1 Deal Description 314.6.2 Deal Analysis 314.7 Alkermes Acquires EDT from Elan in $1 Billion Deal 334.7.1 Deal Description 334.7.2 Deal Analysis 334.8 Celgene Acquires Avila Therapeutics in $947.0m Deal 354.8.1 Deal Description 354.8.2 Deal Analysis 354.9 Jazz Pharmaceuticals Completes $678.4m Acquisition of EUSA Pharma 374.9.1 Deal Description 374.9.2 Deal Analysis 374.10 Jazz Pharmaceuticals Completes $576.5m Merger with Azur Pharma 394.10.1 Deal Description 394.10.2 Deal Analysis 394.11 Biogen Idec Closes $562.5m Deal for the Acquisition of Stromedix 424.11.1 Deal Description 424.11.2 Deal Analysis 425 Licensing Deals 445.1 Overview 445.2 Acorda Signs Marketing License Agreement with Watson Pharma 455.2.1 Deal Description 455.2.2 Deal Analysis 455.3 Baxter Enters Potential $565.0m Deal with Onconova Therapeutics 465.3.1 Deal Description 465.3.2 Deal Analysis 475.4 Exelixis and Merck Involved in "PI3K-?" Licensing Deal 485.4.1 Deal Description 485.4.2 Deal Analysis 485.5 Momenta Enters into Follow-On Biologics Licensing Agreement with Baxter 505.5.1 Deal Description 505.5.2 Deal Analysis 505.6 Nektar and Roche Involved in Manufacturing License Deal 525.6.1 Deal Description 525.6.2 Deal Analysis 526 Collaborations/Partnerships 546.1 Overview 546.2 Ablynx Extends Nanobody Deal with Boehringer Ingelheim 556.2.1 Deal Description 556.2.2 Deal Analysis 566.3 Novartis Pens Partnership with the University of Pennsylvania 576.3.1 Deal Description 576.3.2 Deal Analysis 576.4 Ironwood Enters into Collaboration Agreement with Bionomics 596.4.1 Deal Description 596.4.2 Deal Analysis 596.5 J&J's Janssen Biotech Unit Inks Collaboration Deal with Genmab 606.5.1 Deal Description 606.5.2 Deal Analysis 616.6 Pfizer and Mylan Pharmaceuticals Enter into Generics Manufacturing Partnership 626.6.1 Deal Description 626.6.2 Deal Analysis 627 Future Outlook 657.1 Overview 657.2 Dealmaking Trends 657.2.1 Biotech companies, like Big Pharma, will pursue deals to increase their global presence 657.2.2 "Small Biotech" will continue to engage in M&A in attempts to make the leap to "Big Biotech" 667.2.3 Biotech deal-making will remain a source of IP for Big Pharma 668 Appendix 688.1 Bibliography 688.2 Abbreviations 708.3 Research Methodology 728.3.1 Coverage 728.3.2 Secondary Research 728.3.3 Expert Panel Validation 738.4 About the Authors 738.4.1 Analyst 738.4.2 Global Head of Healthcare Research and Consulting 738.5 About the Industry Dynamics Team 748.6 GlobalData 748.7 Contact Us 758.8 Disclosure Information 758.9 Disclaimer 75

List of Tables

Table 1: Recent and Upcoming US Patent Expirations 12Table 2: M&A Deals, 3Q11-3Q12 20Table 3: Gilead's Acquisition of Pharmasset 24Table 4: GSK's Acquisition of HGS 26Table 5: Valeant Pharmaceutical's Acquisition of Medicis 29Table 6: Amgen's Acquisition of Micromet 30Table 7: Alexion's Acquisition of Enobia Pharma 32Table 8: Alkermes' Acquisition of EDT from Elan 34Table 9: Celgene's Acquisition of Avila Therapeutics 36Table 10: Jazz Pharmaceuticals' Acquisition of EUSA Pharma 38Table 11: Jazz Pharmaceuticals' Merger with Azur Pharma 42Table 12: Biogen's Acquisition of Stromedix 43Table 13: Acorda's Licensing Agreement with Watson Pharma 46Table 14: Acorda's Licensing Agreement with Watson Pharma 48Table 15: Exelixis' Licensing Agreement with Merck 50Table 16: Momenta's Licensing Agreement with Baxter 51Table 17: Nektar's Licensing Agreement with Roche 53Table 18: Ablynx's Collaboration with BI 57Table 19: Novartis' Collaboration with the University of Pennsylvania 58Table 20: Ironwood's Collaboration with Bionomics 60Table 21: Janssen's Collaboration with Genmab 62Table 22: Pfizer's Collaboration with the Mylan Pharmaceuticals 64

List of Figures

Figure 1: FDA Approvals of NDAs and BLAs, FY2005-FY2011 14Figure 2: Deal Analysis - Total Number of Deals and Deal Values ($m), 3Q07-2Q12 16Figure 3: Deal Analysis - Deals Distribution, 3Q07-2Q12 17Figure 4: Top 10 Therapeutic Areas by number and Value of Deals, 3Q11-2Q12 18Figure 5: Biotech Deals Breakdown by Type, Q3 2011-Q3 2012 19Figure 6: M&A Spending, Q3 2011-Q3 2012 ($m) 22Figure 7: Xyrem Sales as Percentage of Jazz Pharmaceuticals' Annual Revenues, 2005-2011 ($m) 40Figure 8: Licensing Deals1, Q3 2011-Q3 2012 44Figure 9: Breakdown of Collaboration deals, Q3 2011-Q3 2012 ($m) 55Figure 10: Pfizer:Emerging Markets Revenues as a Percentage of Annual Revenues, 2006-2011 63

To order this report:Pharmaceutical Industry: Biotech Strategy 2012 - Licensing, Collaboration, and M&A Trends

Nicolas Bombourg



US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. TNI BioTech, Inc. Announces Appointment of New CFO
2. Olympus Biotech International Ltd and BonAlive Biomaterials Ltd Announce Distribution Agreement
3. PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting
4. XBiotech Reports Positive Phase II Interim Analysis Results in Vascular Disease
5. TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC
6. Medical Marijuana Inc. Portfolio Company CanChew BioTechnologies Inc. Announces Final Three Days for Market Survey and Free Product Trial Registration
7. Cytos Biotechnology Ltd Reports Third Quarter 2012 Financial Results, Recent Development and Outlook
8. RayBiotech, Inc. and Abeome Corporation Announce an Agreement Related to Novel Research Products for Ovarian Cancer
9. XBiotech Reports Positive Phase II Interim Analysis Results From Type 2 Diabetes Study
10. Goodwin Biotechnology is a Three-Category Winner in the 2012 CMO Leadership Awards
11. Mersana Therapeutics Named a "Fierce 15" Biotech Company for 2012
Post Your Comments:
(Date:10/9/2015)... Ontario , Oct. 9, 2015 /PRNewswire/ ... radiology furniture, monitor mounting solutions and reading ... Hospital,s Department of Pediatric Radiology realize their ... RedRick Technologies provided ergonomic design guidance and ... clinical collaboration and teaching. George ...
(Date:10/9/2015)... , October 9, 2015 ... --> The report summarizes key ... overall status of the manufacturers making ... and direction for companies and individuals ... . --> ...
(Date:10/9/2015)... PHILADELPHIA , October 9, 2015 ... Conference, Oct. 7-9   ... information products and services, today launched ClinicalKey for Nursing ... authoritative content, tailored to meet the unique needs of nursing ... in Atlanta , Oct. 7-9, will have ...
Breaking Medicine Technology:
... CeQur SA, a company focused on the development ... management of type 2 diabetes, announced the appointment of ... directors, effective immediately. , Milledge is a 34-year ... recently served as company group chairman of Lifescan Inc., ...
... , PITTSBURGH, Oct. 6 Foundation Radiology Group ... services, headquartered in downtown Pittsburgh, recently added Shawn ... growing staff. , Kramer, a 20-year client services ... AT&T Wireless Services, Ceridian, and XO Communications. , ...
Cached Medicine Technology:
(Date:10/9/2015)... ... October 09, 2015 , ... With the FCPX LUT Vibrance pack from ... A LUT is a Lookup Table that contains a mathematical formula for modifying an ... table. This pack comes with 60 vibrant CUBE LUT files. , Inspired ...
(Date:10/9/2015)... ... October 09, 2015 , ... Advanced Hearing Solutions, Nashville based ... Toast of Music City, a reader’s choice awards featuring favorite places to shop, ... for their favorite businesses in over 200 categories, including best pizza, best day ...
(Date:10/9/2015)... ... October 09, 2015 , ... On Saturday, September 26, ... Jump Rope Championship in Madrid, Spain. Representing both the USA and Sweden in the ... Unders and One-Minute Am Front Crosses, she was awarded 1 Silver and 4 Gold ...
(Date:10/9/2015)... ... October 09, 2015 , ... "As a nurse, I care ... Philadelphia, Pa. "They have to wear large diapers or pads. We came up with ... the TROUSAFE to absorb urine leaking from the tip of the penis. This prevents ...
(Date:10/9/2015)... ... October 09, 2015 , ... Santa Rosa Consulting and The ... MD Anderson prepares to go-live on the Epic platform in March of 2016. Both ... Santa Rosa will execute the contract by supporting Scheduling Appointment Conversion and the Go-Live. ...
Breaking Medicine News(10 mins):
... Reporter , MONDAY, Feb. 14 (HealthDay News) -- Obesity and ... of an average of 3.5 years of life in which ... pain, new research finds. Some 40 percent of older ... an often painful and potentially disabling condition that can be ...
... 300-year ancestry of deaf people in America, Richard C. Pillard, ... Medicine (BUSM) and his co-authors argue that deaf people who ... group. The book, "The People of the Eye: Deaf ... people who identify themselves as members of Deaf-World and compares ...
... News) -- Smoking may increase the risk of the fatal ... year in the United States, more than 5,500 people are ... is no cure for the disease and treatments are very ... long-term studies that involved a total of more than 1.1 ...
... HealthDay Reporter , MONDAY, Feb. 14 ... with attention-deficit hyperactivity disorder may reveal insights into ... according to two new studies. In joint ... and the Kennedy Krieger Institute in Baltimore performed ...
... cancer, approximately 25% have a subtype that is characterized ... HER2-positive breast cancer tends to be more aggressive than ... HER2-positive breast cancer is so aggressive could aid in ... a team of researchers, led by Lewis Chodosh, at ...
... This release is available in French . ... Engineering Research Council of Canada (NSERC) awarded 12 prizes ... than C$1 billion, the federal granting agency is the ... Artificial intelligence and machine learning pioneer Geoffrey Hinton was ...
Cached Medicine News:
Indications For Usage: ,Adult (recommended tidal volume >150ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to ...
Indications For Usage: ,Adult (recommended tidal volume >150ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to ...
... The Portex® Thermovent® T helps provide protection ... It is small and extremely lightweight making it ... adults. With a high rate of heat and ... secretion retention., ,All HMEs and filters have ...
... helps provide protection to the exposed airway of ... lightweight making it ideal for active young children ... of heat and moisture recovery, it ensures patient ... and filters have ISO standard tapered ends to ...
Medicine Products: